Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: A population-based cohort study

Breast Cancer Research and Treatment

Volumn 138, Issue 1, 2013, Pages 249-259

  Pastor Barriuso, Roberto ^a,d   Ascunce, Nieves ^b,d   Ederra, María ^b,d   Erdozáin, Nieves ^b,d   Murillo, Alberto ^b   Alés Martínez, José E ^c   Pollán, Marina ^a,d  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^c HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Calibration and discrimination accuracy; Invasive breast cancer; Model recalibration; Risk prediction model; Screening applications; Spanish cohort

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; ETHNIC GROUP; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SPAIN;

EID: 84874646929     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2428-y     Document Type: Article

References (46)

1. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886
2. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541-1548
3. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358-366
4. Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA (2007) Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 99:1695-1705
5. Schonfeld SJ, Pee D, Greenlee RT, Hartge P, Lacey JV Jr, Park Y, Schatzkin A, Visvanathan K, Pfeiffer RM (2010) Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol 28:2411-2417
6. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG (1994) Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 86:620-625
7. Pankratz VS, Hartmann LC, Degnim AC, Vierkant RA, Ghosh K, Vachon CM, Frost MH, Maloney SD, Reynolds C, Boughey JC (2008) Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol 26:5374-5379
8. Meads C, Ahmed I, Riley RD (2012) A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat 132:365-377
9. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388
10. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381-2391
11. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258
12. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40:807-814
13. Boyle P, Mezzetti M, La Vecchia C, Franceschi S, Decarli A, Robertson C (2004) Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. Eur J Cancer Prev 13:183-191
14. Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH (2006) Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation into Cancer and Nutrition cohort. J Natl Cancer Inst 98:1686-1693
15. Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M (2010) Cancer screening in Spain. Ann Oncol 21(Suppl 3):iii43-iii51
16. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr. Accessed Dec 2012
17. Ascunce N, Ederra M, Barcos A, Zubizarreta R, Fernández AB, Casamitjana M (2007) Situación del cribado de cáncer de mama en España: características y principales resultados de los programas existentes. In: Castells X, Sala M, Ascunce N, Salas D, Zubizarreta R, Casamitjana M (eds) Descripción del cribado del cáncer en España. Proyecto DESCRIC. Ministerio de Sanidad y Consumo, Madrid, pp 31-73
18. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg
19. Pollán M, Pastor-Barriuso R, Ardanaz E, Argüelles M, Martos C, Galcerán J, Sánchez-Pérez MJ, Chirlaque MD, Larrañaga N, Martínez-Cobo R, Tobalina MC, Vidal E, Marcos-Gragera R, Mateos A, Garau I, Rojas-Martín MD, Jiménez R, Torrella-Ramos A, Perucha J, Pérez-de-Rada ME, González S, Rabanaque MJ, Borràs J, Navarro C, Hernández E, Izquierdo A, López-Abente G, Martínez C (2009) Recent changes in breast cancer incidence in Spain, 1980-2004. J Natl Cancer Inst 101:1584-1591
20. Ascunce N, Moreno-Iribas C, Barcos-Urtiaga A, Ardanaz E, Ederra-Sanz M, Castilla J, Egüés N (2007) Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme. J Med Screen 14:14-20
21. Registro de Cáncer de Navarra, Instituto de Salud Pública de Navarra. http://www.navarra.es/home-es/Temas/Portal+de+la+Salud/ Profesionales/Planes+y+programas/Registro+de+cancer+de+Navarra. Accessed Dec 2012
22. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (2007) Cancer incidence in five continents, vol IX. International Agency for Research on Cancer, Lyon
23. Benichou J, Gail MH (1990) Estimates of absolute cause-specific risk in cohort studies. Biometrics 46:813-826
24. Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman and Hall, London
25. Gail MH, Pfeiffer RM (2005) On criteria for evaluating models of absolute risk. Biostatistics 6:227-239
26. Pencina MJ, D'Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23:2109-2123
27. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674
28. Banegas MP, Gail MH, LaCroix A, Thompson B, Martinez ME, Wactawski-Wende J, John EM, Hubbell FA, Yasmeen S, Katki HA (2012) Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat 132:347-353
29. Chay WY, Ong WS, Tan PH, Jie Leo NQ, Ho GH, Wong CS, Chia KS, Chow KY, Tan M Sr, Ang P Sr (2012) Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Res 14:R19
30. Ministerio de Sanidad y Consumo (2007) Spanish National Health Survey 2006. Ministerio de Sanidad y Consumo, Madrid. http://www.msps.es/en/ estadEstudios/estadisticas/encuestaNacional/encuesta2006.htm. Accessed Dec 2012
31. Swan J, Breen N, Graubard BI, McNeel TS, Blackman D, Tangka FK, Ballard-Barbash R (2010) Data and trends in cancer screening in the United States: results from the 2005 National Health Interview Survey. Cancer 116:4872-4881
32. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241
33. Ortiz-Moncada R, Álvarez-Dardet C, Miralles-Bueno JJ, Ruíz-Cantero MT, dal Re-Saavedra MA, Villar-Villalba C, Pérez-Farinós N, Serra-Majem L (2011) Social determinants of overweight and obesity in Spain in 2006. Med Clin (Barc) 137:678-684
34. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47-53
35. Benet Rodríguez M, Carvajal García-Pando A, García del Pozo J, Álvarez Requejo A, Vega Alonso T (2002) Hormonal replacement therapy in Spain. Med Clin (Barc) 119:4-8
36. Clavel-Chapelon F, Gerber M (2002) Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat 72:107-115
37. Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389-1399
38. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846
39. Gail MH (2011) Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med 30:1090-1104
40. Gail MH (2008) Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 100:1037-1041
41. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, Thun MJ, Cox DG, Hankinson SE, Kraft P, Rosner B, Berg CD, Brinton LA, Lissowska J, Sherman ME, Chlebowski R, Kooperberg C, Jackson RD, Buckman DW, Hui P, Pfeiffer R, Jacobs KB, Thomas GD, Hoover RN, Gail MH, Chanock SJ, Hunter DJ (2010) Performance of common genetic variants in breast-cancer risk models. N Engl J Med 362:986-993
42. Darabi H, Czene K, Zhao W, Liu J, Hall P, Humphreys K (2012) Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res 14:R25
43. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98:1215-1226
44. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ III, Visscher DW (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353:229-237
45. Schisterman EF, Faraggi D, Reiser B, Trevisan M (2001) Statistical inference for the area under the receiver operating characteristic curve in the presence of random measurement error. Am J Epidemiol 154:174-179
46. Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480-1489